Existing and emerging therapies for the treatment of familial hypercholesterolemia

Area of Science:

• Cardiovascular Medicine
• Metabolic Disorders
• Pharmacology

Background:

• Familial hypercholesterolemia (FH) is an autosomal dominant disorder impacting LDL metabolism, leading to elevated LDL-cholesterol and increased atherosclerotic coronary heart disease risk.
• Current LDL-cholesterol lowering therapies frequently fail to achieve treatment goals, particularly in homozygous FH (HoFH) and high-risk heterozygous FH (HeFH) patients.
• LDL receptor-mediated therapies show limited efficacy in HoFH patients with minimal LDL receptor activity.

Purpose of the Study:

• To provide a treatment framework for adult patients with homozygous FH (HoFH) and heterozygous FH (HeFH).
• To discuss the role of available and emerging LDL-cholesterol lowering therapies.
• To highlight the potential of angiopoietin-like protein 3 inhibitors in managing HoFH and HeFH.

Main Methods:

• Review of current literature on FH treatment strategies.
• Analysis of the efficacy of combined therapies including statins, ezetimibe, and PCSK9 inhibitors.
• Framework development for integrating novel agents like angiopoietin-like protein 3 inhibitors.

Main Results:

• Standard combination therapies often fail to meet LDL-cholesterol goals in over 50% of very high-risk HeFH patients.
• Existing LDL receptor-based treatments are largely ineffective for HoFH patients with very low LDL receptor activity.
• Emerging therapies offer new avenues for achieving LDL-cholesterol targets in FH.

Conclusions:

• Achieving LDL-cholesterol goals in FH, especially HoFH, requires advanced therapeutic strategies beyond current standards.
• A structured approach incorporating novel treatments is crucial for optimizing cardiovascular risk reduction in FH.
• Angiopoietin-like protein 3 inhibitors represent a promising therapeutic option for refractory FH cases.